Observe The Effect And Safety Of Raltitrexed Combinatedoxaliplat/Pirarubicin In Transcatheter Hepatic Arterial Chemoembolization Of Unresectable Primary Liver Cancer

Objective To observe the effect and safety of raltitrexed combinated oxaliplat/pirarubicin in transcatheter hepatic arterial chemoembolization of unresectable primary liver cancer.Metheods Transcatheter hepatic arterial chemoembolization combinated with lobaplatin /floxuridine/pirarubicin were used to treat 35 unresectable primary liver cancer patients. The DSA/MRI/CT/blood routine examination were used to were evaluated the short term activity and toxicity after 4-5 weeks, the process was repeated if necessary. the results were observed.Results Among the 35 cases, 1 case(2.8%) showed a complete response, 23 cases(65.7%) showed a partial response,8 cases(22.8%) showed stable diseaseand, and 5 cases showed progressive disease(14.2%),with a total effective rate of 68.5%. The content of AFP dropped by over 50% in 20(57.1%) cases. The rate of recovery was hepatalgia(89.2%),ascites(48.3 %), appetite(55.3%), engenargy(30.6%).The median follow-up time(MFT)was 283 days( 63-557 days),the median pro-gression-free survival was 118.5 days(95%,CI:88.6-147.1days).Conclusion Transcatheter hepatic arterial chemoembolization with Ratitrexed/oxaliplat/pirarubicin is an effective and safe treatment for primary liver cancer.